.svg)
A clinical guide to GHK-Cu: how this copper-binding tripeptide works, what the research shows for skin and tissue repair, and which biomarkers to track before and during use.
A clinical guide to VIP (vasoactive intestinal peptide): how this endogenous neuropeptide modulates immunity and inflammation, what the research supports across immune regulation, pulmonary function, and neuroprotection, and which biomarkers to monitor before and during use.
An evidence-based review of kisspeptin: the neuropeptide that controls GnRH secretion, the Dhillo-group clinical research program, and the biomarkers relevant to HPG axis evaluation.
An evidence-based review of pentadeca arginate (PDA): what it is, why it is marketed as a BPC-157 alternative, what the preclinical research actually shows, and why no peer-reviewed trials study PDA as a distinct molecule.
An evidence-based review of Selank: the GABA-A allosteric modulation mechanism, what Russian clinical research shows, current FDA regulatory status, and the biomarkers relevant to stress biology.
An evidence-based review of PE-22-28: the TREK-1 channel biology behind this spadin-derived heptapeptide, what preclinical research shows, and why no human safety or efficacy data exists. Superpower does not offer this compound.
A research guide to thymosin alpha-1 (Tα1): how this thymus-derived peptide modulates T-cell development and innate immune signaling, what the published clinical trial evidence shows, and which biomarkers are relevant to the biology it is proposed to affect.
An evidence-based guide to afamelanotide (Scenesse): its selective MC1R mechanism, the clinical trial data supporting FDA approval for erythropoietic protoporphyria, the vitiligo research, and how it differs fundamentally from Melanotan II.
An evidence-based guide to LL-37: how this endogenous cathelicidin works, what the research shows about its dual-edged biology, and the regulatory context for this Category 1 compounded peptide with no FDA-approved indication.
An evidence-based guide to Semax: the ACTH(4-7) analog developed in Russia, how it may influence BDNF and neurotrophin signaling, what the Russian clinical evidence shows, and the regulatory limitations on US use.
An evidence-based review of Pinealon (Glu-Asp-Arg): what the Khavinson bioregulator research shows, its regulatory status, the proposed DNA-binding and oxidative-stress mechanisms, and the single-lab dominance limiting the evidence base.
An evidence-based review of MOTS-c: the 16-amino-acid mitochondrial-derived peptide, the AMPK activation and retrograde signaling mechanisms, the WADA prohibition, and the limits of the current evidence base.
An educational guide to MK-677 (ibutamoren): why it is not a peptide, how it activates the ghrelin receptor to stimulate GH and IGF-1, what Merck's discontinued clinical program found, and what the safety signals mean for its gray-market use.
An evidence-based review of dihexa: what preclinical research shows about this angiotensin IV analog, its proposed HGF/c-Met mechanism, two retracted foundational papers, the c-Met oncogenic concern, and why no human data exists.
An evidence-based review of dermorphin: the D-amino acid structure that makes it 30-40× more potent than morphine at the mu-opioid receptor, the horse-racing doping scandal, safety considerations, and why it has no therapeutic pathway. Superpower does not offer this compound.
An evidence-based review of CJC-1295: how this tetrasubstituted GHRH analog extends growth hormone stimulation, what the DAC and no-DAC variants mean, what the research shows, and which biomarkers are relevant.
An evidence-based review of the GLOW (Klow) peptide blend: what it contains, the research behind GHK-Cu, glutathione, and ascorbic acid, what the evidence shows, and which biomarkers are relevant to the biology it targets.
An evidence-based review of Cerebrolysin: what the clinical research shows across stroke, TBI, and dementia indications, where independent reviewers disagree with industry-sponsored findings, and which biomarkers are relevant to the biology it is proposed to affect. Superpower does not offer this substance.
An evidence-based review of ARA-290 (cibinetide): the innate repair receptor mechanism, clinical trial results in sarcoidosis-associated small-fiber neuropathy, diabetic neuropathy research, and current regulatory and development status. Superpower does not offer this compound.
An evidence-based review of ipamorelin: how this selective ghrelin receptor agonist works, what the published research shows, its regulatory status, and which biomarkers are relevant.
An evidence-based overview of follistatin: the myostatin-inhibiting glycoprotein studied in animal models, gene-therapy trials, and gray-market peptide channels — covering the biology, evidence gaps, and relevant biomarkers.
An evidence-based review of CJC-1295 and ipamorelin as a GHRH-plus-ghrelin-mimetic combination: how each compound works, why they are studied together, what the evidence shows, and which biomarkers are relevant.
An educational guide to AICAR (acadesine): how this AMP-mimetic nucleoside activates AMPK, what preclinical and limited human data show, and why it is prohibited in competitive sport.
An evidence-based review of eloralintide and amycretin: how these next-generation amylin and GLP-1 receptor agonists work, what the clinical trial data shows, and where they stand in the obesity drug pipeline. Superpower does not offer either compound.
An evidence-based review of cagrilintide: how this long-acting amylin analog engages amylin and calcitonin receptors, what Phase 2 monotherapy data shows, and why it is being developed as a component of the CagriSema combination rather than as a standalone therapy.
An evidence-based review of AOD-9604: how this growth hormone fragment works, what human and preclinical studies show, its current regulatory status, and which biomarkers are relevant when exploring GH-axis fat metabolism.
An evidence-based review of adipotide (FTPP): the proapoptotic mechanism targeting adipose vasculature, what the primate research showed, the kidney toxicity signal that stalled clinical development, and relevant biomarkers for anyone exploring metabolic science.
An educational guide to 5-Amino-1MQ: how this small-molecule NNMT inhibitor works, what preclinical studies have found, and why no human trial data currently exists.
An educational guide to SLU-PP-332: what this ERR pan-agonist is, what preclinical mouse studies found, and why no human data or legitimate access pathway currently exists.
Methylene blue is a synthetic phenothiazine dye with preclinical mitochondrial and neuroprotective research. This guide explains how it works, why it appears alongside mitochondrial and nootropic peptides in online discussions, and the safety profile every informed reader should know. This is not a stacking guide.